인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
Abstract SPHK1 is a member of sphingosine kinases (SPHKs), and its abnormal expression has been correlated with poor prognosis and clinicopathological features in cancer patients. Growing evidence points to SPHK1's involvement in cellular resistance to chemotherapy, as well as its role in tumor progression, metastasis, and cancer cell survival. Mechanistically, SPHK1 catalyzes the formation of sphingosine-1-phosphate (S1P), a potent signaling lipid that promotes angiogenesis, metastasis, immune evasion, and survival through S1PR-mediated pathways. Reducing SPHK1 expression through genetic silencing or pharmacological inhibition has been shown in recent research to lessen drug resistance in cancer cells, suggesting that SPHK1 is a potential target for anticancer therapies. For example, SPHK1 inhibitors and anti-S1P monoclonal antibodies could enhance the efficacy of doxorubicin in breast cancer, docetaxel in prostate cancer, and gemcitabine in pancreatic cancer. This review aims to provide a detailed description of the structure and molecular mechanisms that regulate SPHK1. Additionally, we review the interaction between SPHK1 signaling and drug resistance mechanisms separately in various cancers, including breast, gynecological, esophageal, nasopharyngeal, lung, liver, pancreatic, gastric, and colorectal cancers. Finally, we discuss the prospects and challenges of SPHK1 regulation as a therapeutic strategy in resistant cancer therapy. We anticipate that our review will offer valuable insights and provide a foundation for future research. Graphical Abstract
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
